Research done in the 1960s1970s by French Canadian-American microbiologist and virologist Paul Fiset was instrumental in the development of the first successful<unk>  vaccine. Protection is offered by<unk> -Vax, a whole-cell, inactivated vaccine developed by an Australian vaccine manufacturing company, CSL Limited. The intradermal vaccination is composed of killed C. burnetii organisms. Skin and blood tests should be done before vaccination to identify pre-existing immunity, because vaccinating people who already have immunity can result in a<unk> e local reaction. After a single dose of vaccine, protective immunity lasts for many years. Revaccination is not generally required. Annual screening is typically recommended. In 2001, Australia introduced a national<unk>  vaccination program for people working in "at risk" occupations. Vaccinated or previously exposed people may have their status recorded on the Australian<unk>  Register, which may be a condition of employment in the meat processing industry or in veterinary research. An earlier killed vaccine had been developed in the Soviet Union, but its side effects prevented its licensing abroad. Preliminary results suggest vaccination of animals may be a method of control. Published trials proved that use of a registered phase vaccine (Coxevac) on infected farms is a tool of major interest to manage or prevent early or late abortion, repeat breeding, anoestrus, silent oestrus, metritis, and decreases in milk yield when C. burnetii is the major cause of these problems.
Q fever
Leptospirosis
Dysentery
Dengue fever
Enterotoxemia
Malaria
Fever of unknown origin
Pneumonia